New oral option for TGCT when surgery poses risks

The FDA approved a once-daily oral treatment for adults with symptomatic tenosynovial giant cell tumor.

By
Teraya Smith
November 10, 2026
2 min

MDSpire News

At a Glance

Category	Detail
Condition	Symptomatic tenosynovial giant cell tumor (TGCT)
Key Mechanisms	Pimicotinib is an oral kinase inhibitor; the article does not specify its mechanism of action.
Target Population	Adults with symptomatic TGCT for whom surgical resection may worsen functional limitations or cause severe morbidity.
Care Setting	FDA-approved treatment context for adults with measurable TGCT, including at least one lesion measuring 2 cm or larger, when surgery may cause functional impairment or serious complications.

Key Highlights

The FDA approved pimicotinib on November 10, 2026, for adults with symptomatic TGCT when surgery may worsen functional limitations or cause severe morbidity.
Approval was supported by MANEUVER, an international, randomized, double-blind, placebo-controlled trial.
Trial participants were assigned 2:1 to pimicotinib 50 mg or placebo orally once daily.
The recommended dose is 50 mg orally once daily, with or without food.
Warnings and precautions include hepatotoxicity, embryo-fetal toxicity, and increased serum creatinine without an associated effect on renal function.

Guideline-Based Recommendations

Diagnosis

MANEUVER eligibility required confirmed symptomatic TGCT with measurable disease, including at least one lesion measuring 2 cm or larger.

Management

The FDA-approved recommended dosage is pimicotinib 50 mg orally once daily, with or without food.
The approval applies to adults for whom surgical resection may worsen functional limitations or cause severe morbidity.

Monitoring & Follow-up

The prescribing information includes a warning for hepatotoxicity.
Increased serum creatinine is listed as a warning; the article states this was not associated with an effect on renal function.

Risks

Common adverse reactions occurring in more than 20% of patients included pruritus, rash, facial edema, periorbital edema, fatigue, nausea, headache, and peripheral edema.
Laboratory abnormalities reported in more than 30% included elevated creatine phosphokinase, lactate dehydrogenase, aspartate aminotransferase, lipase, cholesterol, amylase, and alanine aminotransferase.
Warnings and precautions include hepatotoxicity and embryo-fetal toxicity.

Patient & Prescribing Data

Adults with symptomatic TGCT for whom surgery may cause functional impairment or serious complications; MANEUVER required measurable disease, including at least one lesion of 2 cm or larger.

Pimicotinib is taken orally at 50 mg once daily, with or without food. In MANEUVER, patients were randomized 2:1 to pimicotinib or placebo.

Clinical Best Practices

Use the FDA-approved indication and dosage described in the prescribing information.
Consider the listed adverse reactions and warnings, including hepatotoxicity and embryo-fetal toxicity, when prescribing.
The article reports that increased serum creatinine was not associated with an effect on renal function.